Smrithi Jayashree Satheeshkumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Smrithi Jayashree Satheeshkumar has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Abhirupa Kar
SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India
2 shared publicationsAnindita Dutta
SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India
2 shared publicationsDipjit Basak
SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India
2 shared publicationsManas Kumar Roy
Department of Gastrointestinal and Hepatobiliary Surgery, Tata Medical Center, Kolkata, India
2 shared publicationsPritha Banerjee
SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India
2 shared publicationsRajgopal Srinivasan
TCS Research, Tata Consultancy Services, Hyderabad, India
2 shared publications
Latest Publications
- 5 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 2833-2847
An Annotated Living Organoid Biobank for Studying Gallbladder Diseases and Drug Responses
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. No suitable models are available to study GBC pathogenesis and drug response. The aim of this study was to establish a biobank comprising patient derived organoids (PDOs) from a wide variety of gallbladder diseases including GBC and other rare pathologies. PDOs were developed from surgically resected gallbladders 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm (PIN); and 13 invasive malignant gallbladder pathologies. Marker expressions, functional activity, histological and gene expression analyses were performed to validate the models. Banked PDOs were retrieved and drug assays performed to assess line-specific responses. Protocol optimization achieved 58% (69/119) and 52% (10/19) success in organoid generation and expansion for all and invasive malignant pathologies, respectively-highest globally for GBC organoids reported to date. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Besides cryopreserved organoids from 62 patients, primary gallbladder tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched Hallmark pathways in XGC support neoplastic changes. Drug response assays demonstrate PDO line-specific response heterogeneity. The developed biobank of PDOs from different gallbladder pathologies provides a promising resource to study gallbladder diseases, investigate the pathogenesis of GBC and study drug responses.
- 5 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 2833-2847
An Annotated Living Organoid Biobank for Studying Gallbladder Diseases and Drug Responses
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. No suitable models are available to study GBC pathogenesis and drug response. The aim of this study was to establish a biobank comprising patient derived organoids (PDOs) from a wide variety of gallbladder diseases including GBC and other rare pathologies. PDOs were developed from surgically resected gallbladders 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm (PIN); and 13 invasive malignant gallbladder pathologies. Marker expressions, functional activity, histological and gene expression analyses were performed to validate the models. Banked PDOs were retrieved and drug assays performed to assess line-specific responses. Protocol optimization achieved 58% (69/119) and 52% (10/19) success in organoid generation and expansion for all and invasive malignant pathologies, respectively-highest globally for GBC organoids reported to date. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Besides cryopreserved organoids from 62 patients, primary gallbladder tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched Hallmark pathways in XGC support neoplastic changes. Drug response assays demonstrate PDO line-specific response heterogeneity. The developed biobank of PDOs from different gallbladder pathologies provides a promising resource to study gallbladder diseases, investigate the pathogenesis of GBC and study drug responses.
- Open Access
Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm and 13 invasive malignant gallbladder pathologies. Protocol optimisation achieved 58% (69/119) success in organoid generation and expansion. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Cryopreserved organoids from 62 patients with primary tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched hallmark pathways in XGC support neoplastic change through chronic inflammation. PDOs generated from different gallbladder pathologies are a promising model to investigate the pathogenesis of GBC. Graphical
Open AccessInsights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm and 13 invasive malignant gallbladder pathologies. Protocol optimisation achieved 58% (69/119) success in organoid generation and expansion. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Cryopreserved organoids from 62 patients with primary tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched hallmark pathways in XGC support neoplastic change through chronic inflammation. PDOs generated from different gallbladder pathologies are a promising model to investigate the pathogenesis of GBC. Graphical
- Open Access
- 24 July 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 1054
Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape
Breast and gynecologic cancers are significant global threats to women’s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer vaccines offer a promising means of inducing long-lasting immune response against the disease. Among various types of cancer vaccines available, peptide vaccines offer an effective strategy to elicit specific anti-tumor immune responses. Peptide vaccines have been developed based on tumor associated antigens (TAAs) and tumor specific neoantigens which can also be of viral origin. Molecular alterations in HER2 and non-HER2 genes are established to be involved in the pathogenesis of female-specific cancers and hence were exploited for the development of peptide vaccines against these diseases, most of which are in the latter stages of clinical trials. However, prophylactic vaccines for viral induced cancers, especially those against Human Papillomavirus (HPV) infection are well established. This review discusses therapeutic and prophylactic approaches for various types of female-specific cancers such as breast cancer and gynecologic cancers with special emphasis on peptide vaccines. We also present a pipeline for the design and evaluation of a multiepitope peptide vaccine that can be active against female-specific cancers.
- 24 July 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 1054
Open AccessPeptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape
Breast and gynecologic cancers are significant global threats to women’s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer vaccines offer a promising means of inducing long-lasting immune response against the disease. Among various types of cancer vaccines available, peptide vaccines offer an effective strategy to elicit specific anti-tumor immune responses. Peptide vaccines have been developed based on tumor associated antigens (TAAs) and tumor specific neoantigens which can also be of viral origin. Molecular alterations in HER2 and non-HER2 genes are established to be involved in the pathogenesis of female-specific cancers and hence were exploited for the development of peptide vaccines against these diseases, most of which are in the latter stages of clinical trials. However, prophylactic vaccines for viral induced cancers, especially those against Human Papillomavirus (HPV) infection are well established. This review discusses therapeutic and prophylactic approaches for various types of female-specific cancers such as breast cancer and gynecologic cancers with special emphasis on peptide vaccines. We also present a pipeline for the design and evaluation of a multiepitope peptide vaccine that can be active against female-specific cancers.